Format

Send to

Choose Destination
Curr Top Med Chem. 2006;6(11):1071-89.

Recent advances in the research and development of RAF kinase inhibitors.

Author information

1
Bayer Research Center, Bayer Pharmaceuticals Corporation, West Haven, CT 06516, USA. roger.smith.b@bayer.com

Abstract

The RAS-RAF-MEK-ERK signaling pathway (ERK pathway) plays a key role in tumorigenesis and cancer progression. Mutations of RAS or B-RAF lead to a constitutive activation of the ERK pathway, which ultimately results in increased cell division, and cell survival. This review article focuses on the recent literature related to ERK pathway inhibitors, with a particular emphasis on RAF kinase inhibitors. Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined.

PMID:
16842147
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center